A carregar...

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placeb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone Rep
Main Authors: Deal, Chad L., Mitlak, Bruce H., Wang, Yamei, Fitzpatrick, Lorraine A., Miller, Paul D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883300/
https://ncbi.nlm.nih.gov/pubmed/31799340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2019.100230
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!